

MEDICAL POLICY UPDATE

IN THIS ISSUE

MCG Custom Guideline Number Changes	5
Additional Notifications	5
Medicare Advantage Policy Changes	4
Commercial Policy Changes	1



Policy

This notification provides an overview of upcoming medical policy changes affecting our Commercial and Medicare Advantage lines of business. Details are outlined in the tables below.

For new policies or those with updated criteria, a direct link is provided in the title of each policy. This link will allow you to view a draft version highlighting the specific changes. Within the draft, additions to the policy are indicated by red underlined text, while deletions are shown as highlighted text with a strikethrough.

Commercial Policy Changes

Policy Change	Commercial Policy Number and Title	Anticipated Issue Date	Impacted States
Archiving	E-5 - Tumor Treatment Fields	10/13/2025	All
Archiving	I-285 - Fidanacogene elaparvovec-dzkt (Beqvez)	10/27/2025	All
Archiving	M-94 - Somatostatin Receptor Scintigraphy	10/6/2025	All
Archiving	S-285 - Spinal Cord and Dorsal Root Ganglion Stimulation	7/18/2025	Pennsylvania, Delaware, West Virginia
Archiving	X-588 - Thyroid Carcinoma Metastases Imaging	10/6/2025	All
No Change in Coverage	E-49 - Seat Lift Mechanisms	10/13/2025	All
No Change in Coverage	I-149 - Chelation Therapy for Off-Label Uses	10/6/2025	All
No Change in Coverage	I-173 - Edaravone (Radicava)	10/13/2025	All
No Change in Coverage	I-199 - Interleukin-23 Antagonists (Ilumya SC and Skyrizi IV)	10/13/2025	All
No Change in Coverage	I-214 - Luspatercept (Reblozyl)	10/6/2025	All

I-253 - Betibeglogene autotemcel (Zynteglo)	10/20/2025	All
I-259 - Entranacogene dezaparvovec (Hemgenix)	10/20/2025	All
I-271 - Valoctocogene Roxaparvovec-rvox (Roctavian)	10/20/2025	All
I-282 - Lovotibeglogene autotemcel (Lyfgenia)	10/27/2025	All
I-76 - Ziconotide (Prialt)	10/13/2025	All
I-90 - Abatacept (Orencia)	10/20/2025	All
L-284 - Laboratory Testing: Medical Necessity	10/13/2025	New York
L-285 - General Approach to Genetic Testing	10/13/2025	New York
M-34 - Electroencephalogram	10/20/2025	All
Pressure Measurement Device	10/13/2025	All
M-88 - Mobile Cardiac Outpatient Telemetry (MCOT)	10/13/2025	All
Q-5 - Ambulance Services: Air and Water	10/13/2025	All
S-118 - Small Bowel, Small Bowel/Liver and Multivisceral Transplant	10/13/2025	All
S-141 - Ablation of Liver Tumors	10/13/2025	All
S-180 - Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions	10/27/2025	All
S-186 - Magnetic Resonance Imaging (MRI)- Guided Focused Ultrasound Surgery (MRgFUS)	10/13/2025	All
S-315 - Hip Surgery: Labral Repair or Reconstruction	10/20/2025	New York
S-316 - Hip Surgery: Femoroacetabular Impingement (FAI)	10/20/2025	New York
S-317 - Hip Surgery: Avascular Necrosis (AVN)	10/20/2025	New York
S-318 - Hip Surgery: Synovectomy	10/20/2025	New York
S-319 - Hip Surgery: Open or Arthroscopic	10/20/2025	New York
S-325 - Lysis of Epidural Adhesions	10/13/2025	New York
S-582 - Cervical Fusion, Anterior	10/20/2025	New York
S-585 - Cervical Laminectomy	10/20/2025	New York
X-21 - Mammography	10/29/2025	All
	I-259 - Entranacogene dezaparvovec (Hemgenix) I-271 - Valoctocogene Roxaparvovec-rvox (Roctavian) I-282 - Lovotibeglogene autotemcel (Lyfgenia) I-76 - Ziconotide (Prialt) I-90 - Abatacept (Orencia) L-284 - Laboratory Testing: Medical Necessity L-285 - General Approach to Genetic Testing M-34 - Electroencephalogram M-81 - Implantable Pulmonary Artery Pressure Measurement Device M-88 - Mobile Cardiac Outpatient Telemetry (MCOT) Q-5 - Ambulance Services: Air and Water S-118 - Small Bowel, Small Bowel/Liver and Multivisceral Transplant S-141 - Ablation of Liver Tumors S-180 - Recombinant and Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions S-186 - Magnetic Resonance Imaging (MRI)- Guided Focused Ultrasound Surgery (MRgFUS) S-315 - Hip Surgery: Labral Repair or Reconstruction S-316 - Hip Surgery: Femoroacetabular Impingement (FAI) S-317 - Hip Surgery: Avascular Necrosis (AVN) S-318 - Hip Surgery: Open or Arthroscopic S-325 - Lysis of Epidural Adhesions S-582 - Cervical Fusion, Anterior	1-259 - Entranacogene dezaparvovec (Hemgenix)

No Change in Coverage	X-584 - Computed Tomography Perfusion Imaging of the Brain	10/6/2025	New York
No Change in Coverage	Z-104 - Basivertebral Nerve Ablation	10/6/2025	All
No Change in Coverage	Z-27 - Eligible Providers	10/13/2025	All
New Policy	E-92 - Alternating Electric Field Therapy- MCG*	10/13/2025	All
New Policy	G-50 - Prademagene zamikeracel (Zevaskyn)	9/1/2025	All
New Policy	I-306 - Injectable Dermal Fillers for Cosmetic Procedures	9/8/2025	All
New Policy	M-89 - Remote Patient Monitoring	11/24/2025	All
Criteria	E-9 - Non-Custom/Custom-Made Gradient	10/13/2025	All
Update	Compression Garments/Stockings/Sleeves	10/10/2020	7 111
Criteria Update	G-49 - Beremagene geperpavec-svdt (Vyjuvek)	9/1/2025	All
Criteria Update	I-122 - Treatment of Hereditary Angioedema (HAE)	9/8/2025	All
Criteria Update	I-129 - Vedolizumab (Entyvio)	10/13/2025	All
Criteria Update	I-218 - Crizanlizumab-tmca (Adakveo)	10/6/2025	All
Criteria Update	I-27 - Certolizumab (Cimzia)	10/20/2025	All
Criteria Update	I-273 - ADAMTS13, recombinant-krhn (Adzynma)	10/20/2025	All
Criteria Update	I-280 - Secukinumab (Cosentyx)	10/20/2025	All
Criteria Update	I-288 - Imetelstat (Rytelo)	9/1/2025	All
Criteria Update	I-305 - Intravesical Mitomycin (Zusduri)	9/1/2025	All
Criteria Update	<u>I-35 - Golimumab (Simponi, Simponi Aria)</u>	10/20/2025	All
Criteria Update	I-37 - Ustekinumab (Stelara) and Ustekinumab Biosimilars	9/1/2025	All
Criteria Update	I-38 - Rituximab (Rituxan), Rituximab Biosimilars, and Rituximab and Hyaluronidase Human (Rituxan Hycela)	10/13/2025	All
Criteria Update	I-4 - Hemophilia Treatment Clotting Factors/Coagulant Blood Products	9/29/2025	All
Criteria Update	L-28 - Tumor Markers	12/8/2025	All
Criteria Update	S-262 - Eustachian Tube Balloon Dilation	10/13/2025	All
Criteria Update	S-275 - Prostate Disease: Diagnosis, Staging, and Treatment	11/24/2025	All
Criteria Update	S-281 - Percutaneous Tenotomy	10/13/2025	All
Criteria Update	S-333 - Osteotomy, Metatarsal	10/13/2025	All
Criteria Update	S-568 - Septoplasty- MCG*	10/13/2025	All

Criteria Update	S-579 - TAVR- MCG*	10/13/2025	All
Criteria Update	S-589 - Functional Endoscopic Sinus Surgery (FESS)- MCG*	10/13/2025	All
Criteria Update	S-67 - Cochlear Implantation	12/8/2025	All
Criteria Update	Z-112 - Epidural Corticosteroid Injection-MCG*	10/13/2025	New York

*MCG Customized Guidelines will be available on the issue date

Medicare Advantage Policy Changes

Policy Category	Medicare Advantage Policy Number and Title	Anticipated Issue Date	Impacted States
Archiving	MA I-296 - Fidanacogene elaparvovec-dzkt (Beqvez)	10/27/2025	All
No Change in Coverage	MA G-55 - Beremagene geperpavec-svdt (Vyjuvek)	9/1/2025	All
No Change in Coverage	MA I-173 - Edaravone (Radicava)	10/13/2025	All
No Change in Coverage	MA I-184 - Certolizumab (Cimzia)	10/20/2025	All
No Change in Coverage	MA I-199 - Interleukin-23 Antagonists	10/13/2025	All
No Change in Coverage	MA I-218 - Golimumab (Simponi, Simponi Aria)	10/20/2025	All
No Change in Coverage	MA I-221 - Crizanlizumab-tmca (Adakveo)	10/6/2025	All
No Change in Coverage	MA I-223 - Luspatercept (Reblozyl)	10/6/2025	All
No Change in Coverage	MA I-269 - Entranacogene dezaparvovec (Hemgenix)	10/20/2025	All
No Change in Coverage	MA I-280 - Valoctocogene Roxaparvovec- rvox (Roctavian)	10/20/2025	All
No Change in Coverage	MA I-289 - Secukinumab (Cosentyx)	10/20/2025	All
No Change in Coverage	MA I-291 - Lovotibeglogene autotemcel (Lyfgenia)	10/27/2025	All
No Change in Coverage	MA I-292 - ADAMTS13, recombinant-krhn (Adzynma)	10/20/2025	All
No Change in Coverage	MA I-299 - Betibeglogene autotemcel (Zynteglo)	10/20/2025	All
No Change in Coverage	MA I-90 - Abatacept (Orencia)	10/20/2025	All
New Policy	MA G-56 - Prademagene zamikeracel (Zevaskyn)	9/1/2025	All
Criteria Update	MA I-122 - Treatment of Hereditary Angioedema (HAE)	9/8/2025	All
Criteria Update	MA I-129 - Vedolizumab (Entyvio)	10/13/2025	All
Criteria Update	MA I-139 - Ustekinumab (Stelara) and Ustekinumab Biosimilars	9/1/2025	All

Criteria Update	MA I-298 - Imetelstat (Rytelo)	9/1/2025	All
Criteria Update	MA I-313 - Intravesical Mitomycin (Zusduri)	9/1/2025	All
Criteria Update	MA I-38 - Rituximab	10/13/2025	MA Delaware, MA Pennsylvania, MA New York



Policy

Additional Notifications

MCG Custom Guideline Number Changes



Highmark Blue Shield has updated the numbers for customized MCG guidelines. Please see the table below for the old and new policy numbers.

These changes went into effect on August 11, 2025.

Customized MCG Guideline Number	Title	New Policy Section	New Number
A-0001	HMK Cardiac Cath and Angiography	Diagnostic Medical	M-93
A-0048	HMK Breast MRI	Radiology	X-586
A-0087	HMK Somatostatin Receptor Scintigraphy	Diagnostic Medical	M-94
A-0101	HMK Breast Ultrasound	Radiology	X-587
A-0167	HMK Cardiac Pacemaker Implantation or Replacement	Surgery	S-347
A-0171	HMK Sclerotherapy Plus Ligation, Saphenofemoral Junction	Surgery	S-348
A-0172	HMK Saphenous Vein Stripping	Surgery	S-349
A-0174	HMK Saphenous Vein Ablation, Radiofrequency	Surgery	S-567
A-0182	HMK Septoplasty	Surgery	S-568
A-0184	HMK Rhinoplasty	Surgery	S-591
A-0225	HMK Epidural Corticosteroid Injection	Miscellaneous	Z-112
A-0250	HMK Hyperbaric Oxygen	Therapy	S-588

A-0270	HMK Brachytherapy	Radiation Therapy & Nuclear Medicine	R-108
A-0340	HMK Intermittent Pneumatic Compression with Extremity Pump	DME	E-91
A-0423	HMK Stereotactic Radiosurgery	Radiation Therapy & Nuclear Medicine	R-109
A-0425	HMK Saphenous Vein Ablation, Laser	Surgery	S-569
A-0455	HMK Intensity Modulated Radiation Therapy	Radiation Therapy & Nuclear Medicine	R-110
A-0532	HMK Breast Cancer Gene Expression Assays	Lab	L-312
A-0579	HMK Thyroid Carcinoma Metastases Imaging	Radiology	X-588
A-0694	HMK Stereotactic Body Radiotherapy	Radiation Therapy & Nuclear Medicine	R-111
A-0735	HMK Stab Phlebectomy	Surgery	S-571
A-0930	HMK Alternating Electric Field Therapy	DME	E-92
A-0948	HMK Disk Arthroplasty, Lumbar	Surgery	S-573
A-1024	HMK Saphenous Vein Ablation, Adhesive Injection	Surgery	S-574
A-1025	HMK Saphenous Vein Ablation, Mechanical Occlusion Chemical Ablation (MOCA)	Surgery	S-575
M-157	HMK Electrophysiologic Study and Implantable Cardioverter-Defibrillator (ICD) Insertion	Surgery	S-576
P-1015	HMK Renal Transplant, Pediatric	Surgery	S-590
P-795	HMK Liver Transplant, Pediatric	Surgery	S-577
S-1015	HMK Renal Transplant	Surgery	S-578
S-1320	HMK TAVR	Surgery	S-579
S-310	HMK Cervical Diskectomy or Microdiskectomy, Foraminotomy, Laminotomy	Surgery	S-581
S-320	HMK Cervical Fusion, Anterior	Surgery	S-582
S-330	HMK Cervical Fusion, Posterior	Surgery	S-583
S-340	HMK Cervical Laminectomy	Surgery	S-585
S-795	HMK Liver Transplant	Surgery	S-586
S-820	HMK Lumbar Fusion	Surgery	S-587



Comments on These Medical Policies?

We want to know what you think about our new medical policy changes. Send us an email with any questions or comments that you may have on the new medical policies in this edition of Medical Policy Update.

Write to us at medicalpolicy@highmark.com



eSubscribe

Subscribe to receive electronic email updates and stay informed about changes to medical policies. Sign up here: Provider Resource Center



About this Newsletter

Medical Policy Update is a monthly newsletter for the health care providers who participate in our networks and submit claims to Highmark using the appropriate HIPAA transactions or claim forms as required by Highmark. This publication focuses only on medical policy and claims administration updates, including coding guidelines and procedure code revisions, and is the sole source for this information. For all other news, information, and updates, be sure to read *Provider News*, available on the <u>Provider Resource Center</u>.

The following entities, which serve the noted regions, are independent licensees of the Blue Cross Blue Shield Association: Central and Southeastern PA: Highmark Inc. d/b/a Highmark Blue Shield, Highmark Benefits Group Inc., Highmark Health Insurance Company, Highmark Choice Company or Highmark Senior Health Company. Northeastern NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Shield.

All references to "Highmark" in this document are references to the Highmark company that is providing the member's health benefits or health benefit administration and/or to one or more of its affiliated Blue companies.

Note: This publication may contain certain administrative requirements, policies, procedures, or other similar requirements of Highmark Inc. (or changes thereto) as well as interpretations of certain administrative requirements, policies and procedures (hereinafter collectively "requirements") which are binding upon Highmark Inc. and its contracted providers. Therefore, the requirements in this publication supplement the Provider Manual. Pursuant to their contract, Highmark Inc. and such providers must comply with any requirements included herein unless and until such item(s) are subsequently modified in whole or in part.